Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AKBA

Akebia Therapeutics Inc.

Dec 01 • 04:00PM ET

1.07

Dollar change +0.01
Percentage change 0.94	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.33	Insider Own	11.33%	Shs Outstand	184.14M	Perf Week	7.00%
Market Cap	201.58M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	0.00%	Shs Float	167.05M	Perf Month	21.32%
Income	-61.09M	PEG	-	EPS next Q	-0.04	Inst Own	18.41%	Short Float / Ratio	5.92% / 7.45	Perf Quarter	-19.55%
Sales	193.61M	P/S	1.04	EPS this Y	37.75%	Inst Trans	-9.77%	Short Interest	9.88M	Perf Half Y	-2.73%
Book/sh	-0.21	P/B	-	EPS next Y	9.71%	ROA	-18.21%	Target Price	4.33	Perf Year	295.56%
Cash/sh	0.25	P/C	4.33	EPS next 5Y	-	ROE	-554.87%	52W Range	0.27 - 1.84	Perf YTD	85.44%
Dividend	-	P/FCF	-	EPS past 5Y	21.17%	ROI	-99.37%	52W High	-41.85%	Beta	0.92
Dividend %	-	Quick Ratio	1.14	Sales past 5Y	14.78%	Gross Margin	53.03%	52W Low	302.86%	ATR	0.07
Employees	205	Current Ratio	1.38	Sales Q/Q	-14.13%	Oper. Margin	-28.87%	RSI (14)	59.49	Volatility	6.87% 8.03%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	72.74%	Profit Margin	-31.56%	Rel Volume	0.90	Prev Close	1.06
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 08 BMO	Payout	-	Avg Volume	1.33M	Price	1.07
Recom	1.00	SMA20	9.02%	SMA50	8.96%	SMA200	3.81%	Volume	1,191,934	Change	0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Resumed	BTIG Research	Buy	$4
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$3.75
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Mizuho	Buy → Neutral	$6 → $2
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $2
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight	$8
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy	$18 → $15
Aug-06-19	Reiterated	H.C. Wainwright	Buy	$19 → $17
Jul-11-19	Reiterated	H.C. Wainwright	Buy	$23 → $21
May-02-19	Initiated	JP Morgan	Overweight	$12
Mar-20-19	Initiated	Citigroup	Neutral	$9
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy	$20 → $18
Jun-06-18	Reiterated	H.C. Wainwright	Buy	$24 → $22
Dec-19-17	Initiated	Piper Jaffray	Overweight	$26
Dec-07-17	Initiated	BTIG Research	Buy	$30
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform	$17

Show Previous Ratings

Dec-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
10:00AM	Top Penny Stocks for Q4 2023 (Investopedia)
Nov-20-23 08:00AM	Akebia Therapeutics to Present at Piper Sandler Healthcare Conference (PR Newswire)
Nov-09-23 11:32AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.20%
Nov-08-23 10:05PM	Q3 2023 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.93%
07:40AM	Loading…
07:40AM	Akebia Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Nov-02-23 04:30PM	Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors (PR Newswire)
Nov-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-31-23 08:00AM	Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights (PR Newswire)
Oct-26-23 10:02AM	Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 08:30AM	Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease (PR Newswire) -6.65%
Oct-18-23 08:00AM	Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023 (PR Newswire)
Oct-03-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.70%
Sep-28-23 08:00AM	Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat (PR Newswire)
08:00AM	Loading…
Sep-26-23 08:00AM	Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update (PR Newswire)
Sep-06-23 08:00AM	Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference (PR Newswire)
Sep-05-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.27%
Aug-31-23 06:15AM	The Petri Dish: Boston Scientific device succeeds in trial, Sanofi vet joins Flagship (American City Business Journals)
Aug-28-23 12:18PM	Is Akebia Therapeutics Inc (AKBA) Set to Underperform? Analyzing the Factors Limiting Growth (GuruFocus.com) +20.00%
11:44AM	Unveiling Akebia Therapeutics (AKBA)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
08:12AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-25-23 10:25PM	Q2 2023 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -8.00%
09:40AM	Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:28AM	Akebia Therapeutics: Q2 Earnings Snapshot (AP Finance)
08:09AM	Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Aug-24-23 08:00AM	Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 (PR Newswire)
Aug-23-23 04:35PM	Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights (PR Newswire)
Aug-17-23 04:05PM	Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023 (PR Newswire)
Aug-10-23 05:40PM	Akebia Therapeutics Provides Update on Form 10-Q Filing (PR Newswire)
04:30PM	Loading…
Aug-01-23 04:30PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +10.18%
Jul-26-23 09:40AM	Are Medical Stocks Lagging InMode (INMD) This Year? (Zacks)
Jul-19-23 07:45AM	Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference (PR Newswire) +5.98%
Jul-18-23 07:45AM	Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023 (PR Newswire)
Jul-06-23 06:07AM	Pocket Change, Big Gains: 3 Penny Stocks Ready to Boom (InvestorPlace)
Jul-05-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-04-23 07:34AM	Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26% (Zacks)
Jun-29-23 08:00AM	Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients (PR Newswire)
Jun-27-23 09:50AM	Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89% (Zacks)
Jun-21-23 08:35AM	Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera (Zacks)
Jun-20-23 08:00AM	Akebia Announces Swissmedic Approval of Vafseo® (vadadustat) (PR Newswire)
Jun-19-23 09:40AM	Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-13-23 07:00AM	Akebia Therapeutics Announces New Chief Financial Officer (PR Newswire)
Jun-08-23 01:20PM	Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been splendid, earning 188% in 1 year (Simply Wall St.)
09:19AM	Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data (Zacks)
Jun-02-23 12:00PM	All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy (Zacks)
09:40AM	Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? (Zacks)
08:30AM	Akebia Therapeutics to Present at Jefferies Healthcare Conference (PR Newswire)
Jun-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-30-23 07:30AM	FDA Provides Akebia Therapeutics a Path Forward for Vadadustat (PR Newswire) -15.17%
May-25-23 08:00AM	Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia (PR Newswire) -15.38%
May-23-23 11:27AM	Why Shares of Akebia Therapeutics Were Up Tuesday (Motley Fool)
May-22-23 05:15PM	Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) +21.55%
08:30AM	Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis (PR Newswire)
May-10-23 09:40AM	Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-09-23 02:12AM	Q1 2023 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 08:45AM	Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
May-04-23 10:00AM	Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know (Zacks) +5.67%
May-01-23 10:01AM	Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know (Zacks)
08:00AM	Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights (PR Newswire)
Apr-25-23 02:30PM	Akebia Receives European Commission Approval for Vafseo (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis (PR Newswire) +6.52%
Apr-19-23 01:07PM	Benign Growth For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Underpins Its Share Price (Simply Wall St.) +6.00%
Apr-14-23 08:30AM	Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split (PR Newswire)
Apr-11-23 11:15AM	Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders (PR Newswire) +13.94%
Apr-07-23 08:30AM	Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023 (PR Newswire)
Apr-04-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.80%
Apr-03-23 08:30AM	Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study (PR Newswire)
Mar-30-23 08:30AM	Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat (PR Newswire) -6.91%
Mar-24-23 08:30AM	Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting (PR Newswire) -6.80%
Mar-13-23 02:51AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.47%
Mar-09-23 10:42PM	Q4 2022 Akebia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -22.26%
08:45AM	Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights (PR Newswire)
Mar-02-23 08:30AM	Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights (PR Newswire)
Feb-23-23 04:05PM	Akebia Receives Positive CHMP Opinion in Europe for Vafseo (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis (PR Newswire) +6.95%
05:34AM	The Petri Dish: Blindness drug approved; Moderna strikes gene-editing deal (American City Business Journals)
Feb-21-23 06:30AM	Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease (PR Newswire) -25.50%
Feb-01-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.35%
Jan-03-23 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.89%
Dec-22-22 08:45AM	Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA (PR Newswire)
Dec-02-22 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-22-22 04:05PM	Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-09-22 06:10AM	Akebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -6.38%
Nov-03-22 06:45PM	Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.34%
04:05PM	Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
Nov-02-22 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-27-22 08:30AM	Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones (PR Newswire)
Oct-21-22 08:30AM	Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 (PR Newswire)
Oct-03-22 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-02-22 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-01-22 08:30AM	Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-05-22 11:12AM	Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Aug-04-22 07:25PM	Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:05PM	Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
04:02PM	Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT) (PR Newswire)
Aug-02-22 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-26-22 08:00AM	Akebia Therapeutics to Report Second Quarter Financial Results (PR Newswire)
Jul-05-22 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.14%
Jun-30-22 04:05PM	Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka (PR Newswire) -7.15%

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dahan Michel	SVP, Chief Operating Officer	May 25	Sale	1.22	95,478	116,760	574,037	May 25 09:01 PM
Hadas Nicole R.	SVP, Chief Legal Officer	May 25	Sale	1.22	63,186	77,270	524,344	May 25 09:01 PM
Burke Steven Keith	SVP, Chief Medical Officer	May 16	Sale	1.07	63,567	67,890	530,487	May 18 06:20 PM
Spellman David A	SVP, CFO and Treasurer	May 16	Sale	1.07	63,567	67,890	446,483	May 18 06:19 PM
Butler John P.	CEO and President	Mar 01	Sale	0.88	91,868	80,614	1,568,872	Mar 03 08:01 AM
Dahan Michel	SVP, Chief Operating Officer	Mar 01	Sale	0.88	20,412	17,912	269,515	Mar 03 08:01 AM
Burke Steven Keith	SVP, Chief Medical Officer	Mar 01	Sale	0.88	14,123	12,393	594,054	Mar 03 08:01 AM
Hadas Nicole R.	SVP, Chief Legal Officer	Mar 01	Sale	0.88	13,034	11,437	287,530	Mar 03 08:01 AM
Spellman David A	SVP, CFO and Treasurer	Mar 01	Sale	0.88	7,210	6,327	510,050	Mar 03 08:00 AM
Butler John P.	CEO and President	Feb 27	Sale	0.81	38,632	31,416	1,660,740	Mar 01 04:07 PM
Dahan Michel	SVP, Chief Operating Officer	Feb 27	Sale	0.81	10,090	8,205	289,927	Mar 01 04:06 PM
Spellman David A	SVP, CFO and Treasurer	Feb 27	Sale	0.81	7,539	6,131	517,260	Mar 01 04:05 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 27	Sale	0.81	7,539	6,131	608,177	Mar 01 04:06 PM
Hadas Nicole R.	SVP, Chief Legal Officer	Feb 27	Sale	0.81	6,677	5,430	300,564	Mar 01 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKBA

Akebia Therapeutics Inc.

Upgrade your FINVIZ experience